A detailed history of Little House Capital LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Little House Capital LLC holds 2,499 shares of VRTX stock, worth $1.2 Million. This represents 0.35% of its overall portfolio holdings.

Number of Shares
2,499
Previous 2,320 7.72%
Holding current value
$1.2 Million
Previous $943,000 10.71%
% of portfolio
0.35%
Previous 0.34%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 18, 2024

BUY
$407.69 - $446.08 $72,976 - $79,848
179 Added 7.72%
2,499 $1.04 Million
Q4 2023

Feb 05, 2024

BUY
$343.0 - $410.68 $294,637 - $352,774
859 Added 58.8%
2,320 $943,000
Q3 2023

Oct 30, 2023

BUY
$338.18 - $362.46 $14,203 - $15,223
42 Added 2.96%
1,461 $508,000
Q2 2023

Jul 18, 2023

BUY
$314.42 - $351.91 $4,401 - $4,926
14 Added 1.0%
1,419 $499,000
Q1 2023

May 04, 2023

BUY
$283.23 - $323.1 $3,398 - $3,877
12 Added 0.86%
1,405 $442,000
Q4 2022

Feb 13, 2023

SELL
$285.76 - $321.48 $4,000 - $4,500
-14 Reduced 1.0%
1,393 $402,000
Q3 2022

Nov 14, 2022

BUY
$273.83 - $305.53 $6,298 - $7,027
23 Added 1.66%
1,407 $407,000
Q2 2022

Aug 12, 2022

SELL
$234.96 - $292.55 $77,771 - $96,834
-331 Reduced 19.3%
1,384 $390,000
Q1 2022

May 16, 2022

BUY
$221.42 - $260.97 $23,913 - $28,184
108 Added 6.72%
1,715 $448,000
Q4 2021

Feb 15, 2022

BUY
$177.01 - $223.45 $51,686 - $65,247
292 Added 22.21%
1,607 $353,000
Q3 2021

Nov 15, 2021

BUY
$181.39 - $202.99 $238,527 - $266,931
1,315 New
1,315 $239,000
Q1 2021

May 17, 2021

SELL
$207.02 - $241.31 $289,620 - $337,592
-1,399 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$207.01 - $276.09 $289,606 - $386,249
1,399 New
1,399 $330,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $124B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Little House Capital LLC Portfolio

Follow Little House Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Little House Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Little House Capital LLC with notifications on news.